Resposta produtiva do cabelo ovinos com a adição alimentar de fenetanolamina / Respuesta productiva del ovino de pelo con la adición alimentaria de la fenetanolamina

Los promotores de crecimiento mejoran el peso animal al incrementar la masa muscular y reducir la adipogénesis.  Los agonistas adrenérgicos como la fenetanolamina al ser adicionado al alimento reducen la grasa corporal tanto en bovinos como en cerdos.  Sin embargo, poca investigación se ha hecho en ovino cruza de Pelibuey en engorda.  Veinticuatro borregos machos de la cruza Pelibuey x Hampshire (peso inicial promedio 23 kg) fueron empleados para evaluar tres niveles de fenetanolamina (Testigo, 0.4, y 0.8 miligramos/kg peso / día) en el alimento a base de sorgo (80%).  El consumo de alimento se alteró ligeramente con el agonista (p < 0.05), pero mejoró la ganancia de peso (g/día; p < 0.05).  La conversión alimenticia disminuyó con la fenetanolamina.  Pero no afecto la cantidad de grasa dorsal (p > 0.05).  En conclusión, se puede decir que el empleo del agonista en cruza de Pelibuey mejora la productividad del animal

Down syndrome as risk factor for respiratory syncytial virus hospitalization : A prospective multicenter epidemiological study

Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality. To compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection. In a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season. The hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively. Infants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered